Scott Eggener, MD

Scott Eggener, MD

David Geffen School of Medicine at UCLA

Los Angeles, California

Scott Eggener, MD, is Professor and Chair of the Department of Urology at the David Geffen School of Medicine at UCLA and Executive Medical Director of Urology for UCLA Health in Los Angeles, California. A nationally recognized urologic oncologist, Dr. Eggener specializes in the diagnosis and treatment of prostate, testicular, and kidney cancers, with expertise in robotic and open surgery.

Dr. Eggener's clinical and research interests focus on improving prostate cancer screening, diagnosis, and treatment, with particular emphasis on reducing overdiagnosis and overtreatment, active surveillance, advanced imaging, biomarkers, and innovative treatment strategies. He has authored or co-authored more than 350 peer-reviewed publications and has participated in numerous clinical trials aimed at improving outcomes for patients with urologic cancers.

Before joining UCLA in 2025, Dr. Eggener served as the Bruce and Beth White Family Professor of Surgery and Vice Chair of Urology at the University of Chicago, where he founded the High-Risk and Advanced Prostate Cancer Clinic.

Dr. Eggener earned his medical degree from Stanford University School of Medicine, completed his urology residency at Northwestern University, and pursued fellowship training in urologic oncology at Memorial Sloan Kettering Cancer Center. He has served on clinical practice guideline panels for the American Urological Association, American Society of Clinical Oncology, and National Comprehensive Cancer Network. He is an Associate Editor of The Journal of Urology and serves on the Board of Directors of the Society of Urologic Oncology.

Talks by Scott Eggener, MD

Image-Guided Focal Treatment of Prostate Cancer

| Nov 2021

Scott Eggener, MD, Professor of Surgery and Radiology and Vice-Chair of Urology at University of Chicago Medicine, discusses image-guided focal therapy and why, despite the challenges of research and adoption of the treatment, it should be researched and taken seriously as a potential standard of care. He explains that focal therapy can be used to minimize unnecessary biopsies and preserve organs. Dr. Eggener then compares the state of breast cancer focal treatment to that of prostate cancer focal treatment by presenting a randomized trial in breast cancer which suggests that prostate cancer care is 50 years behind breast cancer care in this regard. He then states the pros of focal imaging, noting that there have been multiple high-quality trials, that it lowers patients’ likelihood of needing a biopsy, and that it optimizes detection rates. Dr. Eggener then considers the cons of image-guided focal therapy, stating that not all prostate cancer is MR-visible, that MRI tends to underestimate tumor volume, and that MRI is poor at predicting extraprostatic extension. He then summarizes available data on focal therapy showing that vascular targeted photodynamic therapy has much higher outcomes than standard of care, HIFU hemi-ablation has very low rates of salvage therapy or metastases, and gold nanoparticle thermotherapy can result in metastasis-free survival at 1 year after treatment. Dr. Eggener concludes by stating that image-guided focal therapy is worthy of study and physicians should be attentive to results of ongoing and future studies.

Read More